IDXX
$527.07+1.67%
as of close, Oct 5, 2026
☾ AH $527.07 +1.67%
IDEXX Laboratories Inc.Stock · HealthcareS&P 500 Equal Weight 0.2%Nasdaq-100 0.2%Nasdaq Composite 0.10%S&P 500 0.06%Russell 1000 0.06%Russell 3000 0.06%US Stock Market 0.06%MSCI World 0.05%MSCI ACWI 0.04%
IDXX — IDEXX Laboratories Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
100.0200.0300.0400.0500.0600.0700.0010.0M20.0M$527.07—20162019202120242026
2026-10-05
Price$527.07
MA20$549.05
MA50$609.33
Vol1.7M
Key stats#
Price data
- Price
- $527.07
- YTD price return
- -22.09%
- YTD total return
- -22.09%
- Next earnings
- Nov 2, 2026 · Before open
- Market cap
- 41.5B
- Enterprise value
- 41.9B
- Shares outstanding
- 78.8M
- 52W low
- $500.61
- 52W high
- $769.98
- From 52W high
- -31.55%
- From 52W low
- +5.29%
- 52W range
- 10%
- Beta
- 1.54
Volume
- Rel volume
- 1.19×
- 30D volume
- 478.7K
- 30D $ vol
- 252M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$1.2M
- Insider net 1Y
- −$31.0M
Form 4 transactions by trade date, as filed; latest on file 2026-09-04.
Fundamentals
- Sales (ttm)
- 4.6B
- Sales/share
- $57.80
- EPS (ttm)
- $14.22
- FCF (ttm)
- 1.3B
- FCF/share
- $15.92
- Book value/share
- $20.47
- Net margin
- 25.03%
- ROE
- 70.67%
- ROA
- 33.11%
- Debt / equity
- 0.19×
- Current ratio
- 1.17
Growth (CAGR, ttm) · 10Y
- Sales
- +12.78%+9.02%+8.37%+10.42%
- Net income
- +15.64%+12.92%+9.38%+18.90%
- FCF
- +59.97%+28.38%+12.56%+19.00%
- Shares
- -1.53%-1.73%-1.53%-1.27%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +18.48%+14.68%+11.14%+20.46%
- Sales/share
- +14.53%+10.93%+10.05%+11.84%
- FCF/share
- +62.46%+30.63%+14.30%+20.54%
- Book value/share
- +12.26%+15.81%+18.43%n/a
- Price
- -16.09%+6.98%-3.03%+16.65%
- Total return
- -16.09%+6.98%-3.03%+16.65%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 37.1×
- P/OI (ttm)
- 28.5×
- Fwd P/E
- 30.9×
- P/S (ttm)
- 9.1×
- P/B (mrq)
- 25.7×
- P/FCF (ttm)
- 33.1×
- EV/EBITDA (fy)
- 26.0×
- EV/Sales (ttm)
- 9.2×
- FCF yield (ttm)
- 3.02%
- Buyback yield (realized, 1y)
- 1.53%
- Shareholder yield (realized, 1y)
- 1.53%
- Buyback yield (cash, ttm)
- 2.83%
- Shareholder yield (cash, ttm)
- 2.83%
Vs own 10Y history
- P/E
- 1st
- P/OI
- 1st
- P/S
- 30th
- P/B
- 12th
- P/FCF
- 1st
Bar = where today’s multiple sits in IDXX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-05#
1D
+1.67%
5D
-0.38%
1M
-1.55%
3M
-5.51%
YTD
-22.09%
1Y
-16.50%
5Y
-14.27%
Recent filings#
All filings and insider trades →Financial statements
Open full IDXX financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | -0.54% | +0.02% |
| JNJ | Johnson & Johnson | -8.10% | -1.21% |
| ABBV | AbbVie Inc. | +3.63% | +1.12% |
| MRK | Merck & Co. Inc. | -7.18% | -3.30% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -4.67% | +1.80% |
| TMO | Thermo Fisher Scientific Inc. | +10.26% | +3.35% |
| AMGN | Amgen Inc. | -7.83% | -0.01% |
| GILD | Gilead Sciences Inc. | -4.22% | -0.08% |
